New Search Advanced Search

Results

Your search returned '20' results

• Loxapine inhalation for agitation associated with schizophrenia or bipolar disorder

  Agency: NHSC

  Name: Loxapine inhalation (Staccato loxapine, AZ-004)

  Technology Type: Drug Device

  Patient Indications: People with agitation associated with schizophrenia or bipolar disorder.

  Entered On: August 24 2010

• Afatinib for advanced and/or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation

  Agency: NHSC

  Name: Afatinib (BIBW2992)

  Technology Type: Drug

  Patient Indications: NSCLC with EGFR mutation: locally advanced and/or metastatic – first line.

  Entered On: August 18 2010

• Apixaban for stroke prevention in atrial fibrillation

  Agency: NHSC

  Name: Apixaban (BMS 562247; BMS 562247-0)

  Technology Type: Drug

  Patient Indications: Atrial fibrillation (AF) – prevention of stroke in patients with additional risk factor/s for stroke.

  Entered On: August 18 2010

• Axitinib for advanced and/or metastatic renal cell carcinoma – second line.

  Agency: NHSC

  Name: Axitinib (AG 013736; AG 13736; AG-013736; AG-13,736)

  Technology Type: Drug

  Patient Indications: Renal cell carcinoma (RCC): advanced and/or metastatic – second line; after failure of one prior systemic therapy including sunitinib, bevacizumab with interferon alpha, temsirolimus, or cytokines (interferon alpha or interleukin-2).

  Entered On: August 18 2010

• Bevacizumab with trastuzumab and docetaxel for metastatic HER2 positive breast cancer

  Agency: NHSC

  Name: Bevacizumab (Avastin; anti-VEGF monoclonal antibody; R 435; RG435; rhuMAb-VEGF)

  Technology Type: Drug

  Patient Indications: Breast cancer: metastatic; HER2 positive – first line; in combination with trastuzumab and docetaxel.

  Entered On: August 18 2010

• Oral calcitonin for osteoarthritis (OA) of the knee in men and postmenopausal women – first line

  Agency: NHSC

  Name: Oral calcitonin (oral salmon calcitonin, salmon calcitonin, SMC-021)

  Technology Type: Drug

  Patient Indications: Osteoarthritis (OA) of the knee in men and postmenopausal women – first line; monotherapy or in combination with symptom modifying OA drugs.

  Entered On: August 16 2010

• Vorapaxar for acute coronary syndrome

  Agency: NHSC

  Name: Vorapaxar

  Technology Type: Drug

  Patient Indications: Acute coronary syndrome: unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI).

  Entered On: August 17 2010

• Erlotinib hydrochloride (Tarceva) for advanced non-small cell lung cancer with activating mutations

  Agency: NHSC

  Name: Erlotinib hydrochloride (Tarceva, CP-358774, OSI-774, R-1415)

  Technology Type: Drug

  Patient Indications: • Non-small cell lung cancer (NSCLC): locally advanced and/or metastatic; activating EGFR mutations – first line.

  Entered On: August 13 2010

• OncoVEX GM-CSF for unresectable metastatic melanoma – first and second line treatment

  Agency: NHSC

  Name: OncoVEX GM-CSF

  Technology Type: Drug

  Patient Indications: Malignant melanoma: unresectable, locally advanced and/or metastatic – first and second line.

  Entered On: August 16 2010

• Taspoglutide for type 2 diabetes mellitus

  Agency: NHSC

  Name: Taspoglutide

  Technology Type: Drug

  Patient Indications: Type 2 diabetes mellitus - in combination with metformin, or metformin and a sulphonylurea or a thiazolidinedione.

  Entered On: August 16 2010

• Zoledronic acid (Zometa) for hormone-receptor-positive early breast cancer – adjuvant therapy

  Agency: NHSC

  Name: Zoledronic acid (Zometa)

  Technology Type: Drug

  Patient Indications: Early breast cancer: hormone-receptor-positive; premenopausal women – first line; adjuvant therapy in combination with hormonal therapy; patients not suitable for chemotherapy.

  Entered On: August 16 2010

• AIN-457 for posterior uveitis

  Agency: NHSC

  Name: AIN-457

  Technology Type: Drug

  Patient Indications: Chronic non-infectious posterior uveitis – second line; in combination with systemic immunosuppression.

  Entered On: August 16 2010

• Ruxolitinib for myelofibrosis – first line

  Agency: NHSC

  Name: Ruxolitinib (INCB018424, INC-424)

  Technology Type: Drug

  Patient Indications: Myelofibrosis (MF): including primary myelofibrosis (PMF), and MF secondary to polycythaemia vera (PV) and essential thrombocythaemia (ET); patients not eligible for haematopoietic stem cell transplantation (HSCT) - first line.

  Entered On: August 16 2010

• Lenalidomide (Revlimid) for myelodysplastic syndrome (MDS)

  Agency: NHSC

  Name: Lenalidomide (Revlimid, CC-5013)

  Technology Type: Drug

  Patient Indications: Myelodysplastic syndrome (MDS): low or intermediate-1 risk; associated with deletion 5q (del5q) cytogenetic abnormality; red blood cell (RBC) transfusion dependent – first line.

  Entered On: August 16 2010

• Lenalidomide (Revlimid) for newly diagnosed multiple myeloma

  Agency: NHSC

  Name: Lenalidomide (Revlimid, CC-5013)

  Technology Type: Drug

  Patient Indications: Multiple myeloma (MM): newly diagnosed or previously untreated patients; not eligible for autologous stem cell transplant (ASCT) – first line either as: • Induction/treatment – as combination therapy (melphalan and prednisolone, or low-dose dexamethasone). • Maintenance following induction – as monotherapy.

  Entered On: August 16 2010

• Trastuzumab (Herceptin) for early, locally advanced, inflammatory breast cancer – neoadjuvant

  Agency: NHSC

  Name: Trastuzumab (Herceptin)

  Technology Type: Drug

  Patient Indications: • Breast cancer: HER2 positive early, locally advanced and inflammatory – neoadjuvant treatment.

  Entered On: August 16 2010

• Vorapaxar for secondary prevention of cardiovascular events

  Agency: NHSC

  Name: Vorapaxar

  Technology Type: Drug

  Patient Indications: Secondary prevention of thrombotic cardiovascular events in at-risk patients: post myocardial infarction (MI), post ischaemic stroke, or with established peripheral arterial disease (PAD).

  Entered On: August 16 2010

• RG7204 for BRAF V600E mutation positive metastatic malignant melanoma – first or second line

  Agency: NHSC

  Name: RG7204 PLX4032, R7204, RO5185426

  Technology Type: Drug

  Patient Indications: Malignant melanoma: metastatic (stage III or IV); BRAF V600E mutation positive – first or second line.

  Entered On: August 13 2010

• New Oral Device,Thornton Adjustable Positioner (TAP) for Obstructive Sleep Apnoea Syndrome

  Agency: AETS

  Name: Thornton Adjustable Positioner (TAP)

  Technology Type: Device

  Patient Indications: TAP device is indicated in patients suffering Obstructive Sleep Apnoea Syndrome (OSAS) also known as Sleep Apnoea- Hypopnoea Syndrome (SAHS). TAP is also used to treat snoring. Oral appliances are usually indicated in patients with mild to moderate OSAS who prefer Oral Appliances that CPAP, or who do not respond to this treatment, are not appropriate candidates, or who fail treatment attempts with CPAP.

  Entered On: August 6 2010

• Cervista HPV 16/18 test for the detection of HPV16 and HPV18 viral types in cervical infections

  Agency: NHSC

  Name: Cervista HPV 16/18 Test

  Technology Type: Diagnostics

  Patient Indications: • Women aged 30 years and older undergoing routine screening. • Patients with atypical squamous cells of undetermined significance (ASC-US) identified by cervical cytology.

  Entered On: July 7 2010